{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:19:49Z","timestamp":1793420389408,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oral. Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Febrile neutropenia (FN) is a potential life-threatening complication of myelosuppressive chemotherapy, particularly when induced by infection. There is evidence that FN can originate from the oral cavity, but its contribution to FN is largely understudied in patients treated for solid tumors. The aim of this study was to assess the prevalence of FN in these patients and to evaluate its relation with dental foci and oral mucositis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>A prospective longitudinal observational study was conducted. Patients diagnosed with solid tumors and lymphoma scheduled to be treated with myelosuppressive chemotherapy with an intermediate risk of developing FN were included. A pre-chemotherapy dental examination was performed and patients were followed during and after chemotherapy regimen. During subsequent hospital visits for chemotherapy administration, the oral cavity was inspected and oral mucositis (OM) was scored using the CTC-AE version 3.0. When patients presented with fever, a comprehensive full body examination including laboratory\/microbiological\/imaging investigation was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty-eight patients were included. Pre-chemotherapy, 39 patients (44.3%) were diagnosed with a dental focus. During chemotherapy, 46 patients developed OM (53.4%), of which 15 patients had a maximum score of grade II (ulcerative mucositis). Ten patients developed FN during the follow-up period. Patients with FN more often suffered from ulcerative OM compared to patients without FN; both FN and mucositis risk was associated with the myelotoxicity of chemotherapy. However, no relation could be established between the presence of dental foci prior to chemotherapy and the development of FN (<jats:italic>p<\/jats:italic> &amp;gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A significant relation was identified between ulcerative OM and FN, but no robust conclusions could be drawn with respect to a relationship between the presence of dental foci and FN.<\/jats:p><\/jats:sec>","DOI":"10.3389\/froh.2022.940044","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T07:13:03Z","timestamp":1656573183000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma"],"prefix":"10.3389","volume":"3","author":[{"given":"Judith A. E. M.","family":"Zecha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Raber-Durlacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa M. G. A.","family":"Laheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke M.","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludi E.","family":"Smeele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00277-019-03622-0","article-title":"Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"98","author":"Kochanek","year":"2019","journal-title":"Ann Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/annonc\/mdr520","article-title":"Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre","volume":"23","author":"Schelenz","year":"2012","journal-title":"Ann Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen","year":"2005","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1179\/102453310X12583347009577","article-title":"Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes","volume":"15","author":"Jeddi","year":"2010","journal-title":"Hematology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1517\/14656566.2015.1055248","article-title":"Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors","volume":"16","author":"Koinis","year":"2015","journal-title":"Expert Opin Pharmacother."},{"key":"B9","volume-title":"Febrile Neutropenia","author":"Punnapuzha","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4274\/tjh.galenos.2020.2020.0302","article-title":"Timing of blood cultures in the setting of febrile neutropenia: an Australian Institutional Experience","volume":"38","author":"Wang","year":"2021","journal-title":"Turk J Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bjh.13113","article-title":"Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis","volume":"167","author":"van der Velden","year":"2014","journal-title":"Br J Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/odi.13329","article-title":"Should oral foci of infection be removed before the onset of radiotherapy or chemotherapy?","volume":"27","author":"Spijkervet","year":"2021","journal-title":"Oral Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/iej.13467","article-title":"The global prevalence of apical periodontitis: a systematic review and meta-analysis","volume":"54","author":"Tib\u00farcio-Machado","year":"2021","journal-title":"Int Endod J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1007\/s00520-019-04925-8","article-title":"The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy","volume":"27","author":"Zecha","year":"2019","journal-title":"Support Care Cancer."},{"key":"B15","first-page":"557","volume":"145","author":"van Winkelhoff","year":"2001","journal-title":"Ned Tijdschr Geneeskd."},{"key":"B16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12903-020-01221-4","article-title":"Current concepts and an alternative perspective on periodontal disease","volume":"20","author":"Dahlen","year":"2020","journal-title":"BMC Oral Health."},{"key":"B17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00520-002-0346-3","article-title":"Periodontal infection in cancer patients treated with high-dose chemotherapy","volume":"10","author":"Raber-Durlacher","year":"2002","journal-title":"Support Care Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S1368-8375(01)00025-2","article-title":"Periodontal disease and periodontal management in patients with cancer","volume":"37","author":"Epstein","year":"2001","journal-title":"Oral Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5536566","DOI":"10.1155\/2021\/5536566","article-title":"The impact of peri-implantitis on systemic diseases and conditions: a review of the literature","volume":"2021","author":"Radaelli","year":"2021","journal-title":"Int J Dent."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00520-013-1768-9","article-title":"Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas","volume":"21","author":"Chan","year":"2013","journal-title":"Support Care Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/j.1600-051X.2009.01495.x","article-title":"The Dutch periodontal screening index validation and its application in The Netherlands","volume":"36","author":"Van der Velden","year":"2009","journal-title":"J Clin Periodontol."},{"key":"B22","volume-title":"Focus Onderzoek","year":"2016"},{"key":"B23","volume-title":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","year":"2006"},{"key":"B24","volume-title":"Oral Complications of Chemotherapy and Head\/Neck Radiation (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries","author":"Supportive","year":"2002"},{"key":"B25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00520-011-1107-y","article-title":"Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors","volume":"20","author":"Wuketich","year":"2012","journal-title":"Support Care Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00520-006-0055-4","article-title":"Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer","volume":"14","author":"Jones","year":"2006","journal-title":"Support Care Cancer."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/sj.bmt.1702024","article-title":"Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis - are there new strategies?","volume":"24","author":"Karthaus","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.11671","article-title":"The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis","volume":"98","author":"Elting","year":"2003","journal-title":"Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1200\/JCO.2001.19.8.2201","article-title":"Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation","volume":"19","author":"Sonis","year":"2001","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s005200050004","article-title":"Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases","volume":"8","author":"Raber-Durlacher","year":"2000","journal-title":"Support Care Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0182021","DOI":"10.1371\/journal.pone.0182021","article-title":"Intensity and duration of neutropenia relates to the development of oral mucositis but not odontogenic infection during chemotherapy for hematological malignancy","volume":"12","author":"Kishimoto","year":"2017","journal-title":"PLoS ONE."},{"key":"B32","first-page":"72","article-title":"Prevalence of periodontal disease, its association with systemic diseases and prevention","volume":"11","author":"Nazir","year":"2017","journal-title":"Int J Health Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/bjc.2016.60","article-title":"Effect of leaving chronic oral foci untreated on infectious complications during intensive chemotherapy","volume":"114","author":"Schuurhuis","year":"2016","journal-title":"Br J Cancer."}],"container-title":["Frontiers in Oral Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2022.940044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T07:13:13Z","timestamp":1656573193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2022.940044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":33,"alternative-id":["10.3389\/froh.2022.940044"],"URL":"https:\/\/doi.org\/10.3389\/froh.2022.940044","relation":{},"ISSN":["2673-4842"],"issn-type":[{"value":"2673-4842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"article-number":"940044"}}